Trial Profile
An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Rebastinib (Primary) ; Carboplatin
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Malignant-mesothelioma; Neuroendocrine carcinoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Deciphera Pharmaceuticals
- 16 Jan 2024 Status changed from active, no longer recruiting to completed.
- 10 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2021 Planned End Date changed from 1 Oct 2022 to 1 Nov 2022.